Welcome to our dedicated page for Dyadic International news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic International will report its Q3 2021 financial results on November 10, 2021. The company focuses on its proprietary C1-cell protein production platform aimed at enhancing biologic vaccine and drug development. This platform is designed to lower production costs and improve performance. Investors can join a conference call at 5:00 PM ET to discuss these results and the company's future outlook. The C1 technology utilizes the fungus Thermothelomyces heterothallica to produce low-cost proteins efficiently.
Dyadic International (NASDAQ:DYAI) has announced its participation in a virtual investor event on September 13, 2021, presenting at 7 AM ET. Mark Emalfarb, the CEO, will discuss the company's proprietary C1-cell protein production platform aimed at enhancing the development and manufacturing of biologic vaccines and therapeutics. This platform promises to accelerate production, reduce costs, and improve performance, addressing the growing demand for biologics. The conference runs until September 15, 2021, with on-demand access available.
Dyadic International announced a binding term sheet with Sorrento Therapeutics to outlicense its C1 protein production platform for developing vaccines and therapeutics targeting coronaviruses, including its lead candidate DYAI-100. The partnership is expected to generate $10 million upfront and potential milestone payments up to $33 million. The company reported a 66.5% revenue increase year over year and held $25.8 million in cash and securities as of June 30, 2021. Dyadic is advancing its COVID-19 vaccine candidate toward Phase 1 trials, benefiting from new collaborations with Syngene International and the Rubic Consortium.
Dyadic International has signed a binding term sheet with Sorrento Therapeutics granting exclusive rights to utilize its C1 technology across multiple regions for developing vaccines, therapeutics, and diagnostics for coronaviruses, including the lead vaccine candidate DYAI-100. The agreement entails a $10 million upfront payment, potential future milestone payments, and ongoing royalties. This partnership aims to enhance Sorrento's COVID-19 programs and address global immunization needs effectively.
Dyadic International, Inc. (NASDAQ: DYAI) announced it will report its financial results for the second quarter of 2021 on August 12, 2021. The company aims to leverage its proprietary C1-cell protein production platform to enhance the development and production of biologic vaccines and drugs. A conference call will occur at 5:00 p.m. ET, providing investors access to discuss the financial results and company updates.
Interested parties can access the live webcast and replay via designated links provided in the announcement.
Dyadic International has signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium, aimed at improving vaccine access in underserved African regions. The deal facilitates the development of a C1 manufactured COVID-19 vaccine, with milestones to advance through clinical trials. This collaboration aspires to reduce Africa's reliance on foreign vaccines and enhance local production capabilities. Moreover, it potentially impacts coverage for over 40% of the global population. The agreement also supports additional C1 produced vaccines along with DYAI-100.
Dyadic's C1-cell protein production platform has been selected as a rapid response vaccine manufacturing model against zoonotic diseases, demonstrating high efficacy and safety in veterinary target species. The platform can produce recombinant protein-based antigens at significant yields, enabling the development of effective vaccines quickly post-outbreak. The findings from the Zoonotic Anticipation and Preparedness Initiative (ZAPI) indicate a strong potential for C1-cell technology to aid in combating emerging infectious diseases, with positive feedback on immunogenicity and cost-effectiveness of the vaccine doses.
Dyadic International, Inc. (NASDAQ: DYAI) announced a collaboration with Syngene International Ltd. to develop a COVID-19 vaccine candidate that addresses emerging variants. This partnership aims to leverage Dyadic's proprietary C1-cell protein production platform, which promises affordable, large-scale vaccine manufacturing. The collaboration follows a similar partnership with Medytox to enhance vaccine development in Korea and Southeast Asia.
Dyadic's CEO emphasized the urgent need for effective vaccines and the potential of their technology to facilitate rapid response to infectious diseases.
Dyadic International (NASDAQ:DYAI) announced its participation in key upcoming events, including the Jefferies Virtual Healthcare Conference on June 1, 2021, where CEO Mark Emalfarb will discuss advancements in its C1-cell protein production platform. This platform focuses on reducing costs for vaccines and drugs, particularly the COVID-19 vaccine candidate, DYAI-100, preparing for Phase 1 trials. Additionally, Dyadic will present at the BIO International Convention from June 10-18. A live webcast will be available on their website for both events.
Dyadic International (DYAI) is advancing its COVID-19 vaccine candidate, DYAI-100, towards a Phase 1 clinical trial aimed at proving safety and efficacy. The company aims to produce larger quantities of affordable COVID-19 vaccines using its proprietary C1 technology. Recent financial results indicate a revenue increase to $461,000 for Q1 2021, with R&D expenses rising to $1.8 million due to clinical trial costs. As of March 31, 2021, cash and equivalents were $27.4 million. Collaborations with Medytox and others are ongoing to develop variant vaccines.